Practical Geriatrics ›› 2022, Vol. 36 ›› Issue (10): 1042-1045.doi: 10.3969/j.issn.1003-9198.2022.10.016

Previous Articles     Next Articles

Effect of recombinant human brain natriuretic peptide on myocardial injury markers in elderly patients with acute left heart failure

DING Chao, CHU Yue-feng, FENG Jun   

  1. DING Chao. Department of Cardiology, Lu'an Civily Hospital, Lu'an 237000, China;
    CHU Yue-feng, FENG Jun. Department of Cardiology, Lu'an People's Hospital, Lu'an 237008, China
  • Received:2021-11-23 Online:2022-10-20 Published:2022-10-21

Abstract: Objective To study the effect of recombinant human brain natriuretic peptide (rhBNP) on the levels of myocardial injury markers in the elderly patients with acute left heart failure. Methods From November 2016 to November 2019, 80 patients with acute left heart failure in our hospital were enrolled. They were randomly divided into the observation group and the control group, with 40 cases in each group. Both groups received routine treatment after admission. The observation group was treated with rhBNP, and the control group was treated with nitroglycerin additionally. The clinical efficacy, cardiac function indexes [ left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF), left ventricular short axis shortening rate (LVFS) ], myocardial injury markers [ creatine kinase (CK), lactate dehydrogenase (LDH), N-terminal pro-brain natriuretic peptide (NT-proBNP) and cardiac troponin I (cTnI) ] and the incidence of adverse reactions were compared between the two groups after treatment. Results The total effective rate of cardiac function improvement in the observation group was significantly higher than that in the control group(P<0.05).The levels of LVESD and LVEDD in the two groups after treatment were significantly lower than those before treatment, while the levels of LVEF and LVFS were significantly higher than those before treatment(P<0.05). The levels of cTnI, CK, LDH and NT-proBNP in the two groups after treatment were significantly lower than those before treatment(P < 0.05),especially in the observation group(P<0.05). The incidence rate of the adverse reactions in the observation group was significantly lower than that in the control group (P<0.05). Conclusions rhBNP can significantly improve the therapeutic effect in the elderly patients with acute left heart failure, improving the cardiac function, reducing the cardiac load, improving the level of myocardial injury markers, with less side effects.

Key words: recombinant human brain natriuretic peptide, aged, acute left heart failure, myocardial injury

CLC Number: